The FDA has notified healthcare professionals that drug interactions between the hepatitis C virus (HCV) protease inhibitor Victrelis (boceprevir; Merck) and certain ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitors can potentially reduce the effectiveness of these medicines when they are used together.
Salix announced that the FDA has granted priority review designation of its New Drug Application (NDA) for crofelemer 125mg tablets for the control and symptomatic relief of diarrhea in patients with HIV/AIDS on anti-retroviral therapy (ART).
Liver-like cells produced from an individual’s own cells can support the entire life cycle of hepatitis C virus, potentially making it possible to study why people respond differently to the virus.
Antiretroviral drugs prescribed for HIV-infected pregnant women to reduce risk of mother-to-child disease transmission may be linked to cleft lip and palate disorders in newborns.
Chimerix announced final data from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus in hematopoietic cell transplant recipients.
Direct-acting antiviral agents may be effective for treating patients with chronic hepatitis C virus (HCV) genotype 1 who don’t respond to peginterferon and ribavirin therapies.
Gilead Sciences announced that the FDA has approved Viread (tenofovir disoproxil fumarate) in combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients 2-12 years old.
The reintroduction of the rotavirus vaccination in the United States has not resulted in an increase in the rate of infant hospital discharges for intussusception.
Adenovirus-based vaccines can generate strong, broad, long-lasting, and functional T cell responses against hepatitis C virus (HCV) in healthy people.
Antiepileptic drugs (AEDs) should be used with caution in individuals with HIV/AIDS, due to potential interactions between AEDs and antiretroviral agents (ARVs).
